For more than 145 years, we have been working tirelessly to develop and deliver medicines that meet real needs. Learn more about Lilly's portfolio of medicines.
Irish laws and regulations limit the amount of product information that we can provide to the public on our website. The product information on this website is intended for Irish residents over the age of eighteen years only.
Abasaglar ® (insulin glargine)
Adcirca ®* (tadalafil)
Alimta ® (pemetrexed)
Cialis ® (tadalafil)
Cymbalta ® (duloxetine)
Emgality ® ▼ (galcanezumab)
Forsteo ® (teriparatide)
Humalog ® (human insulin analogue)
Humulin ® (human insulin)
Olumiant ® (baricitinib)
Strattera ® (atomoxetine)
Taltz ® (ixekizumab)
Trulicity ® (dulaglutide)
Yentreve ® (duloxetine)
Zypadhera ® (olanzapine pamoate monohydrate)
Zyprexa ® (olanzapine)
Devices - Instructions for Use
* Lilly is the marketing authorisation holder (MAH) but does not promote this product.
The following Lilly medicine is subject to additional monitoring: Emgality ® ▼. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.hpra.ie for how to report side effects.
Report an Adverse Event or Product Complaint:
If you experience side effects whilst taking a Lilly medicine, talk to your doctor or other healthcare professional. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide information on the safety of medicines.
Please do not use this website to report side effects or complaints about a Lilly product.
Information placed on this website is not intended as a substitute for consultation with your healthcare professional.